The Medical Device Authority (MDA) of Malaysia has announced that the Medical Device Directive (Designated Medical Devices) 2026 has been gazetted and will officially take effect on 1 June 2026. This marks a new phase in Malaysia’s regulatory oversight of medical aesthetic devices.
The key information is summarized as follows:
I. Key Highlights
Effective Date
The Directive has been formally gazetted, with mandatory enforcement commencing on 1 June 2026. Companies are provided with an approximately five-month preparation period prior to enforcement.
Regulatory Objective
The Directive aims to strengthen and standardize the regulation of medical devices used for medical aesthetic purposes, ensuring their safety, quality, and systematic use.
Clearly Defined Scope of Application
The announcement specifies that the Directive will introduce more comprehensive regulatory control over certain medical devices used in cosmetic and aesthetic treatments. The covered device categories include, but are not limited to:
- Laser treatment devices
- High-Intensity Focused Ultrasound (HIFU) devices
- Liposuction devices
- Other related therapeutic equipment
Regulatory Intent
Through this Directive, the MDA seeks to protect the public from risks associated with the use of devices that do not meet safety standards, while enhancing public confidence and safety in medical aesthetic services. At the same time, the regulation is intended to promote the sustainable and responsible development of the medical aesthetic industry within a compliant regulatory framework.
Follow-Up Arrangements
Prior to the effective date of 1 June 2026, the MDA will continue to engage and collaborate with all stakeholders, including practitioners, industry operators, and the public, to ensure the smooth implementation of the Directive.
II. Impact on Medical Aesthetic Companies and In-Depth Analysis
Clearly Targeted Industry
This Directive is specifically aimed at the medical aesthetic sector. Companies involved in the manufacture, importation, distribution, sale, and use of relevant devices will be the primary regulatory subjects.
Upgraded Compliance Requirements
Once the Directive enters into force, any “designated medical devices” supplied to or used in the Malaysian market must comply with a new and comprehensive set of regulatory requirements established by the MDA. These requirements may cover:
- Product registration
- Premises licensing
- Personnel qualifications
- Operational and clinical practice standards
- Advertising and promotion controls
- Adverse event reporting obligations
Higher Market Entry Threshold
For companies planning to introduce new or existing medical aesthetic devices into the Malaysian market, it is essential to assess the impact of the new Directive on current registrations and future market entry strategies. Products that fail to meet the new regulatory requirements may face market access restrictions or prohibition from the effective date onward.
Transitional Arrangements
The MDA has indicated its intention to work closely with the industry to ensure a smooth transition. Companies are strongly encouraged to proactively initiate compliance preparations well in advance of 1 June 2026, rather than adopting a wait-and-see approach.
Conclusion
MDA’s legislative action in the medical aesthetic field sends a clear signal of more refined, risk-based regulatory oversight. While this presents challenges in terms of compliance and operational readiness, it also creates opportunities to enhance safety standards, normalize market practices, and strengthen the competitiveness of high-quality enterprises.
GRZAN operates its own Malaysia-based subsidiary with GDPMD certification and is well positioned to assist medical device companies—including those in the medical aesthetic sector—with registration applications and to act as the local certificate holder.
Please feel free to contact us for further information.